AFFILIATIONS
1 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
2 Columbia University Herbert Irving Comprehensive Cancer Center, New York, United States
3 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
4 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
5 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
6 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
7 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
8 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
9 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
10 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
11 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
12 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
ABSTRACT
Background: R-CHOP is the standard first-line therapy for diffuse large B-cell lymphoma (DLBCL), however, only 60% of patients are cured. Selinexor, a first-in-class selective inhibitor of nuclear export (SINE), inhibits exportin 1 (XPO1) and has demonstrated synergistic antitumor activity with CHOP in preclinical models of non-Hodgkin lymphoma. In a phase I study, the recommended phase II dose (RP2D) of selinexor in combination with R-CHOP was established as 60 mg once weekly (Seymour et al., AACR 2021). We evaluated the safety and efficacy of selinexor plus R-CHOP in patients with previously untreated DLBCL (ClinicalTrials.gov Identifier: NCT03147885).
Methods: This multicenter, investigator-initiated, phase II dose-expansion study enrolled adults (≥18 years) with previously untreated stage III–IV DLBCL, ECOG performance status ≤1, and FDG-avid measurable disease by PET. Patients received six 21-day cycles of standard-dose R-CHOP plus oral selinexor 60 mg on Days 1, 8, and 15 of each cycle. Patients achieving a complete or partial response after induction were eligible to receive optional selinexor maintenance therapy (60 mg weekly on Days 1, 8, 15, and 22 of a 28-day cycle) for up to 1 year. G-CSF prophylaxis was mandatory. The primary endpoint was 2-year progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), complete response (CR) rate, overall survival (OS), and safety. Patients who discontinued treatment or died before the first disease assessment were not considered response evaluable. Exploratory analyses evaluated the association between baseline XPO1 expression (IHC) and clinical outcomes as well as longitudinal tracking of XPO1, p53, FOXO3a in the blood.
Results: Thirty-one patients were enrolled. The median age was 63 years (range, 29–75), and 61.3% had non-germinal center B-cell (non-GCB) subtype. IPI score was 3 in 32.3% of patients, while 9.7% had an IPI score of 4. Double-expressor lymphoma and double-hit lymphoma were identified in 22.6% and 3.2% of patients, respectively. Overall, 74.2% (n=23) completed all six induction cycles, 64.5% (n=20) received selinexor maintenance and 38.7% (n=12) completed 1 year of selinexor maintenance. Among response evaluable patients (n=27), the ORR was 92.6% (95% CI, 76.6-97.9%), including a CR rate of 74.1%. After a median follow-up of 33.7 months for PFS, the estimated 2-year PFS and OS were 69.4% (90% CI, 56.7-85.0%) and 79.1% (95% CI, 65.5-95.6%), respectively; median PFS and OS were not reached. Treatment related adverse events (TRAEs) of any grade occurred in 96.8% of patients, with grade 3–4 TRAEs reported in 51.6%. The most common grade 3–4 TRAEs were neutropenia (19.4%), infections (9.7%), lymphopenia (9.7%), and febrile neutropenia (9.7%). Two patients (6.5%) died during induction cycles, while induction treatment was discontinued for progression in 2 patients (6.5%) and AEs in 4 patients (12.8%). Correlative analyses identified distinct pharmacodynamic modulation of XPO1 and FOXO3a during treatment, characterized by an early increase followed by progressive suppression in many patients, whereas p53 expression exhibited greater interpatient variability. Ongoing analyses are evaluating whether baseline XPO IHC expression and longitudinal biomarker trajectories correlate with treatment response and clinical outcomes. These comprehensive correlative data will be presented at the conference.
Conclusions: The addition of selinexor to R-CHOP did not significantly improve durable remission rates in patients with treatment naïve DLBCL and was associated with a high rate of treatment discontinuation.
DISCLOSURES
Dipenkumar Modi, MD: Regeneron - Honoraria; Dava Oncology - Honoraria; Genentech - Research Funding; Genmab - Research Funding; AstraZeneca - Research Funding; Karyopharm Therapeutics - Research Funding; AstraZeneca - Consultancy (Includes expert testimony); Bristol Meyers Squibb - Consultancy (Includes expert testimony); Scitech Development Inc - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Bristol-Meyers Squibb - Consultancy (Includes expert testimony)